IDO1 and melanoma: In this study, the mice with B16 melanoma were resistant to CTLA-4 treatment but when the CTLA-4 treatment was combined with IDO inhibitor 1- methyltryptophan (1MT) the tumors showed sensitivity to anti-CTLA-4.